Cytokinetics, IncorporatedCYTKNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank23
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P23
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -32.69% |
| Q3 2025 | 16.17% |
| Q2 2025 | 2.57% |
| Q1 2025 | -100.73% |
| Q4 2024 | 35.40% |
| Q3 2024 | -2.20% |
| Q2 2024 | 23.31% |
| Q1 2024 | -74.92% |
| Q4 2023 | 23.04% |
| Q3 2023 | 21.02% |
| Q2 2023 | 0.39% |
| Q1 2023 | -24.54% |
| Q4 2022 | -20.29% |
| Q3 2022 | 9.78% |
| Q2 2022 | -237.45% |
| Q1 2022 | 40.07% |
| Q4 2021 | -15.39% |
| Q3 2021 | -31.44% |
| Q2 2021 | 0.08% |
| Q1 2021 | -156.60% |
| Q4 2020 | 262.98% |
| Q3 2020 | 152.36% |
| Q2 2020 | 8.95% |
| Q1 2020 | -58.15% |
| Q4 2019 | 5.98% |
| Q3 2019 | 17.87% |
| Q2 2019 | 8.29% |
| Q1 2019 | -118.28% |
| Q4 2018 | 61.76% |
| Q3 2018 | -20.07% |
| Q2 2018 | 9.93% |
| Q1 2018 | -23.83% |
| Q4 2017 | 5.54% |
| Q3 2017 | 18.48% |
| Q2 2017 | -49.26% |
| Q1 2017 | -126.91% |
| Q4 2016 | 742.05% |
| Q3 2016 | -8.06% |
| Q2 2016 | 35.92% |
| Q1 2016 | -76.09% |